Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Cerulean Pharma Closes $15 Million Series D Financing: New Investor CVF, LLC Joins Venture Syndicate

Abstract:
-Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that it has closed a $15 million Series D financing with participation from new investor, CVF, LLC, an affiliate of Henry Crown and Company of Chicago, Illinois, as well as full participation from all other existing investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, and Bessemer Venture Partners. In conjunction with the closing of the financing, Robert Paull, a co-founder and managing partner at Lux Capital, has joined Cerulean's board of directors as the director designated jointly by Lux Capital and CVF, LLC.

Cerulean Pharma Closes $15 Million Series D Financing: New Investor CVF, LLC Joins Venture Syndicate

Cambridge, MA | Posted on December 15th, 2011

"To maximize and continue the progress across our portfolio of opportunities, we decided to raise an additional round at this time. I am excited to welcome CVF to our strong investor syndicate"

The financing proceeds will be used to complete a randomized Phase 2 trial of CRLX101 in non-small cell lung cancer, and to support several investigator-sponsored CRLX101 Phase 2 trials in additional indications at leading academic medical centers. Additionally, Cerulean's docetaxel nanopharmaceutical candidate will be advanced into clinical trials, and the Company will aggressively pursue other platform expansion opportunities, including the delivery of RNA-based therapeutics.

"To maximize and continue the progress across our portfolio of opportunities, we decided to raise an additional round at this time. I am excited to welcome CVF to our strong investor syndicate," said Oliver Fetzer, Ph.D., president and chief executive officer of Cerulean. "This financing will allow us to further develop CRLX101 in non-small cell lung cancer and explore additional important indications while advancing a set of pre-clinical nanopharmaceutical programs, including one for RNAi delivery."

####

About Cerulean Pharma Inc.
Cerulean Pharma Inc. is a clinical-stage company specializing in the design and development of nanopharmaceuticals optimized to make drugs more effective and with fewer side effects. Cerulean is applying its proprietary nanopharmaceutical platform technologies and specialized capabilities to advance a new class of therapeutic agents for diseases with unmet medical needs. With an initial focus in oncology, the Company’s technology platform can be readily applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs. Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, Bessemer Venture Partners, and CVF, LLC. Cerulean’s offices and lab facilities are located in Cambridge, Massachusetts.

For more information, please click here

Contacts:
Kathy Vigneault
Account Executive
Schwartz MSL Boston
a: 300 Fifth Avenue, 1st Floor, Waltham, MA 02451
o: 781.684.6571

w: schwartzmsl.com

Copyright © Cerulean Pharma Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New solar power material converts 90 percent of captured light into heat: SunShot Project aims to make solar cost competitive October 29th, 2014

Tiny carbon nanotube pores make big impact October 29th, 2014

Microrockets fueled by water neutralize chemical and biological warfare agents October 29th, 2014

Nanosafety research – there’s room for improvement October 29th, 2014

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014

7th Nanotechnology Festival, Exhibition Kicks Off Work in Iran October 7th, 2014

Harris & Harris Group Letter to Shareholders on Website August 19th, 2014

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 August 12th, 2014

Nanomedicine

'Electronic skin' could improve early breast cancer detection October 29th, 2014

Tiny carbon nanotube pores make big impact October 29th, 2014

Molecular beacons shine light on how cells 'crawl' October 27th, 2014

New nanodevice to improve cancer treatment monitoring October 27th, 2014

Announcements

New solar power material converts 90 percent of captured light into heat: SunShot Project aims to make solar cost competitive October 29th, 2014

Tiny carbon nanotube pores make big impact October 29th, 2014

Microrockets fueled by water neutralize chemical and biological warfare agents October 29th, 2014

Nanosafety research – there’s room for improvement October 29th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE